CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $80,128,453
- in 11 filings, $80.1M under 10b5-1 plans
Net −$80,128,453. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-17 | LYONS GARY A Director | Sale 10b5-1 | −2,600 | $63.50 | $165K | 62,000 |
| 2026-08-17 | LYONS GARY A Director | Sale 10b5-1 | −500 | $64.16 | $32K | 61,500 |
| 2026-08-17 | LYONS GARY A Director | Option exercise · Stock option (right to buy) 10b5-1 | −5,000 | 5,000 | ||
| 2026-06-22 | Inrig Jula CHIEF MEDICAL OFFICER | Gift | −468 | 112,770 | ||
| 2026-06-12 | Baynes Roy D. Director | Option exercise 10b5-1 | +4,500 | $21.38 | $96K | 46,000 |
| 2026-06-12 | Baynes Roy D. Director | Sale 10b5-1 | −4,500 | $50.00 | $225K | 41,500 |
| 2026-06-12 | Baynes Roy D. Director | Option exercise · Stock option (right to buy) 10b5-1 | −4,500 | 0 | ||
| 2026-06-12 | Coughlin Timothy Director | Option exercise 10b5-1 | +10,000 | $26.52 | $265K | 66,250 |
| 2026-06-12 | Coughlin Timothy Director | Sale 10b5-1 | −10,000 | $50.07 | $501K | 56,250 |
| 2026-06-12 | Coughlin Timothy Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 0 | ||
| 2026-05-19 | Baynes Roy D. Director | Grant or award | +4,000 | 41,500 | ||
| 2026-05-19 | Baynes Roy D. Director | Grant or award · Stock option (right to buy) | +12,000 | 12,000 | ||
| 2026-05-19 | Poole Sandra Director | Grant or award | +4,000 | 34,000 | ||
| 2026-05-19 | Poole Sandra Director | Grant or award · Stock option (right to buy) | +12,000 | 12,000 | ||
| 2026-05-19 | Bruhn Suzanne Louise Director | Grant or award | +4,000 | 32,750 | ||
| 2026-05-19 | Bruhn Suzanne Louise Director | Grant or award · Stock option (right to buy) | +12,000 | 12,000 | ||
| 2026-05-19 | Meckler Jeffrey A Director | Grant or award | +4,000 | 91,500 | ||
| 2026-05-19 | Meckler Jeffrey A Director | Grant or award · Stock option (right to buy) | +12,000 | 12,000 | ||
| 2026-05-19 | Orwin John A Director | Grant or award | +4,000 | 39,375 | ||
| 2026-05-19 | Orwin John A Director | Grant or award · Stock option (right to buy) | +12,000 | 12,000 |
Page 6 of 41 · 802 trades